Indicated for: obesity; weight management
Route of administration: oral
Substance: rimonabant (CB1 receptor antagonist)
ATC: A08AX01 (Alimentary tract and metabolism | Antiobesity preparations, excl. diet products | Other antiobesity drugs)
Rimonabant is a medication that was previously used for the treatment of obesity and metabolic syndrome. It acts as an antagonist of cannabinoid type 1 (CB1) receptors, reducing appetite and aiding in weight loss.
The medication was withdrawn from the market in many countries due to associated risks, such as severe depression and suicidal tendencies. It is important for patients who have used this medication to be monitored for potential adverse effects.
Patients should be aware of potential side effects, such as nausea, anxiety, or sleep disturbances. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, anxiety, and sleep disturbances. In rare cases, severe reactions such as severe depression or suicidal tendencies may occur. Patients should be informed of these risks before use.